Desidustat

Summary

Desidustat (CHEMBL4650314) is a phase-3 clinical-stage small molecule targeting EGLN2; indicated across 3 conditions including chronic kidney disease and severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (EGLN2)
• Indications: 3 conditions
• Clinical trials: 5
• Chemistry: 332.31 Da · C16H16N2O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650314
Name	Desidustat
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	75593290
Molecular formula	C16H16N2O6
Molecular weight	332.31
InChIKey	IKRKQQLJYBAPQT-UHFFFAOYSA-N

SMILES: C1CC1CON2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O

IUPAC name: 2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid

Also known as: Desidustat, Zyan-1, ZYAN1, DESIDUSTAT

Patent coverage: 110 distinct patent families (254 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 224 (88%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
EGLN2	egl-9 family hypoxia inducible factor 2	Inhibition		4.6%	Q96KS0

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Gamma-butyrobetaine dioxygenase, Bifunctional peptidase and arginyl-hydroxylase JMJD5, Aspartyl/asparaginyl beta-hydroxylase, Egl nine homolog 1.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
BBOX1	6.38	IC50	420	nM	CHEMBL_ACT_29204379
EGLN1	5.89	IC50	1300	nM	CHEMBL_ACT_29204490
ASPH	5	IC50	9900	nM	CHEMBL_ACT_29204499

Target pathways

Aggregated over 1 target gene(s): EGLN2.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha	1	EGLN2

Dominant GO biological processes

GO term	Targets
regulation of cell growth	1
response to hypoxia	1
peptidyl-proline hydroxylation to 4-hydroxy-L-proline	1
estrogen receptor signaling pathway	1
regulation of neuron apoptotic process	1
cell redox homeostasis	1
positive regulation of protein catabolic process	1
cellular response to hypoxia	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic kidney disease	3	MONDO:0005300	EFO:0009909
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE4	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05515367	PHASE4	RECRUITING	A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)
NCT04012957	PHASE3	COMPLETED	Desidustat in the Treatment of Anemia in CKD
NCT04215120	PHASE3	COMPLETED	Desidustat in the Treatment of Anemia in CKD on Dialysis Patients
NCT04463602	PHASE2	COMPLETED	Desidustat in the Management of COVID-19 Patients
NCT04667533	PHASE1	COMPLETED	Desidustat in the Treatment of Chemotherapy Induced Anemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

5 molecules share ≥1 primary target. Top 5 by shared-target count:

Molecule	Source	Status	Shared targets
MOLIDUSTAT	ChEMBL + PubChem	Phase 2 (approved)	EGLN2
anhydrous citric acid	PubChem	Approved	EGLN2
ascorbic acid	PubChem	Approved	EGLN2
Malic Acid	PubChem	Approved	EGLN2
Oxygen	PubChem	Approved	EGLN2